These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30818412)

  • 1. Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation.
    Umutlu L; Beyer T; Grueneisen JS; Rischpler C; Quick HH; Veit-Haibach P; Eiber M; Purz S; Antoch G; Gatidis S; Nikolaou K; Schaefer JF; Rausch I; Herrmann K; ;
    Nuklearmedizin; 2019 Mar; 58(2):68-76. PubMed ID: 30818412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation.
    Umutlu L; Beyer T; Grueneisen JS; Rischpler C; Quick HH; Veit-Haibach P; Eiber M; Purz S; Antoch G; Gatidis S; Nikolaou K; Schaefer JF; Rausch I; Herrmann K; ;
    Rofo; 2019 Apr; 191(4):289-297. PubMed ID: 30818411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hybrid imaging for detection of carcinoma of unknown primary: A preliminary comparison trial of whole-body PET/MRI versus PET/CT.
    Ruhlmann V; Ruhlmann M; Bellendorf A; Grueneisen J; Sawicki LM; Grafe H; Forsting M; Bockisch A; Umutlu L
    Eur J Radiol; 2016 Nov; 85(11):1941-1947. PubMed ID: 27776644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
    Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
    J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimized workflow and imaging protocols for whole-body oncologic PET/MRI.
    Ishii S; Hara T; Nanbu T; Suenaga H; Sugawara S; Kuroiwa D; Sekino H; Miyajima M; Kubo H; Oriuchi N; Ito H
    Jpn J Radiol; 2016 Nov; 34(11):754-762. PubMed ID: 27714486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous whole-body time-of-flight 18F-FDG PET/MRI: a pilot study comparing SUVmax with PET/CT and assessment of MR image quality.
    Iagaru A; Mittra E; Minamimoto R; Jamali M; Levin C; Quon A; Gold G; Herfkens R; Vasanawala S; Gambhir SS; Zaharchuk G
    Clin Nucl Med; 2015 Jan; 40(1):1-8. PubMed ID: 25489952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
    J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of PET and MR datasets in integrated 18F-FDG PET/MRI: A comparison of different MR sequences for whole-body restaging of breast cancer patients.
    Grueneisen J; Sawicki LM; Wetter A; Kirchner J; Kinner S; Aktas B; Forsting M; Ruhlmann V; Umutlu L
    Eur J Radiol; 2017 Apr; 89():14-19. PubMed ID: 28267530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
    Gatidis S; Schmidt H; Gücke B; Bezrukov I; Seitz G; Ebinger M; Reimold M; Pfannenberg CA; Nikolaou K; Schwenzer NF; Schäfer JF
    Invest Radiol; 2016 Jan; 51(1):7-14. PubMed ID: 26309185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [PET-based measurements in oncology: PET/CT and PET/MRI applications].
    Borbély K; Garai I; Baranyai T; Patkó PZ
    Magy Onkol; 2020 Jun; 64(2):87-96. PubMed ID: 32520001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reporting guidance for oncologic 18F-FDG PET/CT imaging.
    Niederkohr RD; Greenspan BS; Prior JO; Schöder H; Seltzer MA; Zukotynski KA; Rohren EM
    J Nucl Med; 2013 May; 54(5):756-61. PubMed ID: 23575994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of integrated whole-body PET/MR and PET/CT: Is PET/MR alternative to PET/CT in routine clinical oncology?
    Ishii S; Shimao D; Hara T; Miyajima M; Kikuchi K; Takawa M; Kumamoto K; Ito H; Shishido F
    Ann Nucl Med; 2016 Apr; 30(3):225-33. PubMed ID: 26676720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Structured reporting in oncologic hybrid imaging: a consensus recommendation].
    ; ;
    Rofo; 2020 Aug; 192(8):739-744. PubMed ID: 32544953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining optimal tracer activities in pediatric oncologic whole-body
    Gatidis S; Schmidt H; la Fougère C; Nikolaou K; Schwenzer NF; Schäfer JF
    Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2283-2289. PubMed ID: 27565153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer.
    Sakurai Y; Kawai H; Iwano S; Ito S; Ogawa H; Naganawa S
    J Med Imaging Radiat Oncol; 2013 Jun; 57(3):297-305. PubMed ID: 23721138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases.
    Iagaru A; Young P; Mittra E; Dick DW; Herfkens R; Gambhir SS
    Clin Nucl Med; 2013 Jul; 38(7):e290-6. PubMed ID: 23455520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
    Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
    Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
    Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
    Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffusion-weighted imaging as part of hybrid PET/MRI protocols for whole-body cancer staging: does it benefit lesion detection?
    Buchbender C; Hartung-Knemeyer V; Beiderwellen K; Heusch P; Kühl H; Lauenstein TC; Forsting M; Antoch G; Heusner TA
    Eur J Radiol; 2013 May; 82(5):877-82. PubMed ID: 23428414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study.
    Klenk C; Gawande R; Uslu L; Khurana A; Qiu D; Quon A; Donig J; Rosenberg J; Luna-Fineman S; Moseley M; Daldrup-Link HE
    Lancet Oncol; 2014 Mar; 15(3):275-85. PubMed ID: 24559803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.